Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jazeta is a DPP‑4 inhibitor used within the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus (monotherapy): improves glycaemic control when combined with diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glucose regulation when added to metformin or other antidiabetic agents. - Type 2 diabetes mellitus (adjunct therapy): supports overall blood‑sugar management as part of a comprehensive treatment plan.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Upper respiratory tract infection: mild nasal congestion or sore throat. - Headache: transient and usually mild. - Nasopharyngitis: inflammation of the nasal passages and throat. - Gastrointestinal discomfort: occasional nausea or abdominal pain. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Acute renal failure: sudden loss of kidney function in susceptible patients.

Before initiating therapy, consider the following safety measures. - Renal function: assess creatinine clearance and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor for any worsening of heart conditions. - Concomitant medications: review all drugs for potential interactions. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Sitagliptin may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: heightened risk of hypoglycaemia, monitor glucose levels. - Diuretics (e.g., thiazides): may affect renal clearance of sitagliptin. - Antihypertensives: observe blood pressure changes when combined with fluid‑retaining agents.